Savara (SVRA) Total Current Liabilities (2010 - 2026)
Savara (SVRA) reported Total Current Liabilities of $15.5 million for Q1 2026, up 30.6% year-over-year from $11.9 million in Q1 2025, and down 23.81% quarter-over-quarter from $20.4 million in Q4 2025.
Savara (SVRA) Total Current Liabilities (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Total Current Liabilities data on file, last reported at $15.5 million in Q1 2026.
- Total Current Liabilities for Q1 2026 came in at $15.5 million, up 30.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.5 million (up 30.6% YoY), and the FY2025 annual result was $20.4 million, up 38.52% from the prior year.
- Total Current Liabilities eased to $15.5 million in Q1 2026 per SVRA's latest filing, from $20.4 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $20.4 million in Q4 2025 and troughed at $3.7 million in Q2 2022.
- A 5-year average of $11.1 million and a median of $11.3 million in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 126.49% in 2022, then sank 69.85% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $5.9 million in 2022, then jumped by 80.62% to $10.6 million in 2023, then jumped by 38.94% to $14.7 million in 2024, then soared by 38.52% to $20.4 million in 2025, then fell by 23.81% to $15.5 million in 2026.
- Business Quant data shows SVRA's Total Current Liabilities at $15.5 million in Q1 2026, $20.4 million in Q4 2025, and $16.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 13.42 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 72.86 Mn |
| 10 | Savara | 1.28 Bn | 1.28 Bn | - | 15.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.54 Mn |
| Dec 31, 2025 | 20.40 Mn |
| Sep 30, 2025 | 16.76 Mn |
| Jun 30, 2025 | 13.63 Mn |
| Mar 31, 2025 | 11.90 Mn |
| Dec 31, 2024 | 14.72 Mn |
| Sep 30, 2024 | 12.79 Mn |
| Jun 30, 2024 | 11.29 Mn |
| Mar 31, 2024 | 9.81 Mn |
| Dec 31, 2023 | 10.60 Mn |
| Sep 30, 2023 | 8.96 Mn |
| Jun 30, 2023 | 5.89 Mn |
| Mar 31, 2023 | 4.92 Mn |
| Dec 31, 2022 | 5.87 Mn |
| Sep 30, 2022 | 5.16 Mn |
| Jun 30, 2022 | 3.71 Mn |
| Mar 31, 2022 | 16.32 Mn |
| Dec 31, 2021 | 14.66 Mn |
| Sep 30, 2021 | 10.66 Mn |
| Jun 30, 2021 | 5.64 Mn |